Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of UCB Pharma S.A.

    Client Virtual Booth

    UCB PHARMA S.A

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    UCB Pharma S.A
    Belgium Flag
    Country
    Country
    Belgium
    Address
    Address
    Allée de la Recherche, 60 1070 Brussels
    Telephone
    Telephone
    +32 2 559 99 99
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ucb.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional ...

    Details:

    Bimzelx (bimekizumab) is an IL-17A and IL-17F inhibitor, which is being evaluated for the treatment of adults with moderate-to-severe hidradenitis suppurativa.


    Lead Product(s): Bimekizumab

    Therapeutic Area: Dermatology Product Name: Bimzelx

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 04, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    UCB receives Positive CHMP Opinion for BIMZELX[®]▼(bimekizumab) for the Treatment of Adults with Moderate to Severe Hidradenitis Suppurativa

    Details:

    Bimzelx (bimekizumab) is a humanized IgG1 monoclonal antibody that selectively binds to IL-17A, IL-17F and IL-17AF cytokines. It is being evaluated for the treatment of adults with moderate-to-severe hidradenitis suppurativa.


    Lead Product(s): Bimekizumab

    Therapeutic Area: Dermatology Product Name: Bimzelx

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 22, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

    Details:

    Bimzelx (bimekizumab) is a humanized IgG1 monoclonal antibody that selectively binds to IL-17A, IL-17F and IL-17AF cytokines. It is being evaluated for the treatment of adults with moderate-to-severe hidradenitis suppurativa.


    Lead Product(s): Bimekizumab

    Therapeutic Area: Dermatology Product Name: Bimzelx

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 08, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    UCB announces Strategic Investment in IMIDomics, Inc to Advance Breakthrough Solutions for Immune-Mediated Inflammatory Diseases

    Details:

    The net proceeds will be used to the advancement of novel medicines, including IMB1001, a highly promising humanized antibody targeting CD226, for immune-mediated inflammatory diseases (IMIDs).


    Lead Product(s): IMB1001

    Therapeutic Area: Immunology Product Name: IMB1001

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Recipient: IMIDomics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Financing March 04, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    UCB Announces European Commission Approval of RYSTIGGO® (rozanolixizumab) for the tReatment of Adults with Generalized Myasthenia Gravis in Europe

    Details:

    Rystiggo (rozanolixizumab) is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor (FcRn) resulting in the reduction of circulating IgG. It is approved by EMA for generalized myasthenia gravis.


    Lead Product(s): Rozanolixizumab

    Therapeutic Area: Immunology Product Name: Rystiggo

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 08, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Ant...

    Details:

    Zilbrysq (zilucoplan) is FDA-approved as the first and only self-administered C5 complement inhibitor indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-AChR antibody positive.


    Lead Product(s): Zilucoplan

    Therapeutic Area: Immunology Product Name: Zilbrysq

    Highest Development Status: ApprovedProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 03, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    UCB announces European Commission Approval of ZILBRYSQ[®]▼ (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

    Details:

    Zilbrysq (zilucoplan) is a C5 inhibitor peptide drug candidate, which is currently being evaluated for the treatment of patients with AChR antibody-positive generalized myasthenia gravis.


    Lead Product(s): Zilucoplan

    Therapeutic Area: Immunology Product Name: Zilbrysq

    Highest Development Status: ApprovedProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 04, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

    Details:

    Bimzelx (bimekizumab) is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both IL-17A and IL-17F, two key cytokines driving inflammatory processes, received positive CHMP opinion for severe plaque psoriasis.


    Lead Product(s): Bimekizumab

    Therapeutic Area: Dermatology Product Name: Bimzelx

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 14, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    UCB Receives CHMP Positive Opinion for Rozanolixizumab for Treatment of Adults with Generalized Myasthenia Gravis in Europe

    Details:

    Rystiggo (rozanolixizumab) is an FcRn Binder antibody drug candidate, which is currently being evaluated for the treatment of adult patients with generalized myasthenia gravis.


    Lead Product(s): Rozanolixizumab

    Therapeutic Area: Immunology Product Name: Rystiggo

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 10, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    BIMZELX[®] Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

    Details:

    Bimzelx (bimekizumab) is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both IL-17A and IL-17F, two key cytokines driving inflammatory processes, received positive CHMP opinion for severe plaque psoriasis.


    Lead Product(s): Bimekizumab

    Therapeutic Area: Dermatology Product Name: Bimzelx

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 18, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search